Naloxone Spray Global Market Report 2024

Naloxone spray is a substance that binds to opioid receptors, effectively inhibiting or reversing the actions of other opioids. Administering naloxone promptly can counteract the effects of opioid medications and restore normal breathing. This can be achieved through intravenous injection or nasal spray. Naloxone is typically dispensed as a solution in liquid form, designed for spraying into the nose, with each nasal spray containing a single dose intended for one-time use.

The main dosage options for naloxone spray are 2 mg/actuation and 4 mg/actuation. The 2 mg/actuation naloxone spray, equivalent to 1.8 mg of naloxone, is utilized as an emergency medication for known or suspected opioid overdose, as indicated by respiratory and/or central nervous system depression. The 2 mg dose is licensed for use in opioid-dependent individuals at risk of severe opioid withdrawal, residing in an environment with low risk of accidental or intentional opioid exposure from household contacts. Naloxone sprays are available through various distribution channels, including hospitals, clinics, retail pharmacies, online pharmacies, and others.

The naloxone spray market research report is one of a series of new reports that provides naloxone spray market statistics, including naloxone spray industry global market size, regional shares, competitors with a naloxone spray market share, detailed naloxone spray market segments, market trends and opportunities, and any further data you may need to thrive in the naloxone spray industry. This naloxone spray market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The naloxone spray market size has grown exponentially in recent years. It will grow from $540.68 billion in 2023 to $668.6 billion in 2024 at a compound annual growth rate (CAGR) of 23.7%. The growth observed in the historical period can be attributed to several factors, including the increased prevalence of opioid overdose, a rise in cases of opioid drug abuse particularly in developed countries, advancements in drug development, an increasing awareness regarding the importance of naloxone spray, and a general growth in healthcare expenditure.

The naloxone spray market size is expected to see exponential growth in the next few years. It will grow to $1592.93 billion in 2028 at a compound annual growth rate (CAGR) of 24.2%. The anticipated growth in the forecast period can be attributed to supportive government initiatives promoting naloxone distribution, the expansion of accessibility programs for naloxone, an increase in prescription rates for opioid analgesics, and ongoing efforts to address and combat the opioid crisis. Major trends expected in the forecast period include the adoption of intranasal naloxone formulations, the development of user-friendly naloxone devices, the integration of naloxone education in opioid prescribing practices, and the inclusion of naloxone in community-based harm reduction programs.

The growth of the naloxone spray market is attributed to the increasing prevalence of opioid overdoses. Opioids, including morphine, fentanyl, and tramadol, are utilized for pain treatment, but their non-medical use, prolonged usage, misuse, or unsupervised use can lead to opioid dependence and severe health complications, including fatalities. According to a Centers for Disease Control and Prevention (CDC) report in February 2021, opioids were involved in 70.6% of all drug overdose deaths, totaling 49,860 cases. Naloxone nasal spray plays a crucial role in emergency medical treatment by reversing the life-threatening effects of opioid overdoses, thereby driving the growth of the naloxone spray market.

The anticipated growth of the naloxone spray market is also linked to the increasing demand for telemedicine. Telemedicine, or telehealth, utilizes technology to provide remote medical services, offering comprehensive and immediate support to individuals at risk of opioid overdose. This approach proves valuable in addressing the opioid crisis effectively. In April 2023, National telehealth use increased by 7.3%, reaching 5.9% of medical claim lines, according to FAIR Health Inc. The rising demand for telemedicine contributes to the expansion of the naloxone spray market.

Product approvals are playing a pivotal role in shaping the naloxone spray market. Key manufacturers of naloxone sprays are focused on obtaining approvals for new products to diversify their portfolios and enhance their presence in the naloxone spray business. For example, in April 2021, the US Food and Drug Administration (FDA) approved Hikma Pharmaceuticals' KLOXXADOTM nasal spray for the immediate treatment of opioid overdose. This approval represents a significant step in addressing the opioid epidemic and provides an effective solution to reverse the effects of opioid overdose.

Major companies in the naloxone spray market are directing their efforts towards innovative products like Narcan to boost market revenues. Narcan nasal spray, launched by Sandoz International GmbH in December 2021, is designed to rapidly reverse the effects of opioid overdoses, including those caused by heroin, fentanyl, morphine, or prescription opioid painkillers. It acts swiftly to block the impact of opioids on the brain, restoring normal breathing and consciousness in individuals experiencing an overdose.

In March 2021, Aptar Pharma, a US-based pharmaceutical company, announced a collaboration with DNE Pharma, a Norwegian pharmaceutical company, to develop addiction medicines. This partnership, utilizing Ford Pharma's Ventizolve nasal naloxone, focuses on enhancing patient access and addressing the opioid epidemic through training programs and expertise in nasal drug delivery treatment for opioid overdoses.

Major companies operating in the in the naloxone spray market report are Emergent BioSolutions Inc., Amphastar Pharmaceuticals Inc., Hikma Pharmaceuticals plc, Indivior plc, Nasus Pharma LLC, Neon Laboratories Limited, Opiant Pharmaceuticals Inc., Pfizer Inc., Samarth Pharma Pvt. Ltd., Teva Pharmaceutical Industries Ltd., Troikaa Pharmaceuticals Ltd., Adapt Pharma Inc., AmerisourceBergen Corporation, Cardinal Health Inc., CVS Health Corporation, Express Scripts Holding Company, Harm Reduction Coalition Inc., Kaleo Inc., McKesson Corporation, Mundipharma International Limited, Mylan N. V., NextDistro Inc., Rite Aid Corporation, Novartis International AG, Sandoz International GmbH, Fresenius Kabi USA LLC, Hospira Inc., West-Ward Pharmaceuticals Corp., Walgreens Boots Alliance Inc., Lupin Ltd.

North America was the largest region in the naloxone spray market in 2023. The regions covered in the naloxone spray market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the naloxone spray market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.

The naloxone spray market consists of sales of injectable and prepackaged nasal spray. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified)).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.